$5.23
4.39%
Nasdaq, May 02, 10:00 pm CET
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Immatics N.V Stock price

$5.23
+1.06 25.42% 1M
-4.12 44.06% 6M
-1.88 26.44% YTD
-5.66 51.97% 1Y
-2.64 33.55% 3Y
-9.82 65.25% 5Y
-9.82 65.25% 10Y
Nasdaq, Closing price Fri, May 02 2025
+0.22 4.39%
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Key metrics

Market capitalization $635.71m
Enterprise Value $28.37m
P/E (TTM) P/E ratio 64.89
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.17
P/S ratio (TTM) P/S ratio 3.77
P/B ratio (TTM) P/B ratio 1.07
Revenue growth (TTM) Revenue growth 188.64%
Revenue (TTM) Revenue $168.59m
EBIT (operating result TTM) EBIT $-41.77m
Free Cash Flow (TTM) Free Cash Flow $-185.93m
Cash position $625.91m
EPS (TTM) EPS $0.08
P/E forward negative
P/S forward 7.90
EV/Sales forward 0.35
Short interest 7.07%
Show more

Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Immatics N.V Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Immatics N.V forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Immatics N.V forecast:

Buy
100%

Financial data from Immatics N.V

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
169 169
189% 189%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
7% 7%
14%
- Research and Development Expense 160 160
25% 25%
95%
-29 -29
72% 72%
-17%
- Depreciation and Amortization 13 13
69% 69%
8%
EBIT (Operating Income) EBIT -42 -42
62% 62%
-25%
Net Profit 16 16
115% 115%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immatics N.V Stock News

Neutral
GlobeNewsWire
12 days ago
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Societ...
Negative
Seeking Alpha
about one month ago
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.
Neutral
GlobeNewsWire
about one month ago
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.
More Immatics N.V News

Company Profile

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Head office Netherlands
CEO Harpreet Singh-Jasuja
Employees 423
Founded 2020
Website www.immatics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today